Objective To analyze the basic characteristics of hospitalized patients with colorectal cancer (CRC), to estimate the hospitalization scale, medical resource utilization, and cross-regional hospitalization of CRC inpatients in Sichuan Province, which will provide data support for scientifically formulating colorectal cancer medical resource allocation measures. Methods Based on the hospital discharge records of CRC inpatients collected from secondary hospitals and tertiary hospitals in Sichuan Province between 2015 and 2019, descriptive statistical analysis was performed and the cross-geographical hospitalizations was visualized using a directed network. Results During the study period, the number of CRC inpatients and hospitalizations increased with time. The average age of CRC inpatients in 2019 was 65.1 years, an increase of 1.5 years in the 5-year-period. The proportion of men was relatively high (about 60.1%) and remained stable in the 5-year-period. The median length-of-stay of CRC inpatients per year was 25 days (IQR: 13 days, 45 days), and inpatients in urban areas were 2 days longer than that in rural areas. The median hospitalization cost of CRC inpatients per year was 32 900 yuan (IQR: 11 200 yuan, 59 300 yuan), men were 500 yuan higher than women, and patients in urban areas were 9 900 yuan higher than that in rural areas. From 2016 to 2019, 13.9% hospitalizations (59 512 hospitalizations) were cross-geographical hospitalizations, where Chengdu had the lowest outflow rate (1.0%) and the highest inflow rate (29.3%). Conclusions CRC inpatients showed an aging trend, and the number of hospitalizations and annual hospitalization costs increased year by year. Cross-geographical hospitalizations mainly flow to the provincial medical center and a small part flow to the regional medical centers.
ObjectiveTo analyze the impact of preoperative hypoproteinemia on postoperative complications in patients with rectal cancer based on the current version of the Database from Colorectal Cancer (DACCA). MethodsThe patient information was extracted from the updated version of DACCA in April 2024 according to predefined inclusion criteria. The preoperative hypoproteinemia and incidence of complications were analyzed. The univariate and multivariate logistic regression analyses were performed to identify risk factors for complications in three postoperative periods (in-hospital, short-term, and long-term). The test level was α=0.05. ResultsA total of 1 440 patients with rectal cancer were included, 322 (22.4%) with preoperative hypoproteinemia and 1 118 (77.6%) without. Compared to the patients without preoperative hypoproteinemia, those with preoperative hypoproteinemia were older (P<0.001), had a lower body mass index (P<0.001), smaller tumor margins (P=0.032), and a higher proportion of patients with pTNM stage Ⅳ (P<0.001). There were no statistically significant differences in the overall incidence of complications during the three postoperative periods (in-hospital, short-term, and long-term) between the patients with and without preoperative hypoproteinemia (χ2=0.399, P=0.280; χ2=0.298, P=0.585; χ2=1.416, P=0.234). Except for urinary retention, there were no significant differences in the incidence of specific complications between the two groups (P>0.05). The univariate and multivariate logistic regression analyses did not identify preoperative hypoproteinemia as a risk factor for postoperative complications (P>0.05). ConclusionsThe results of this study suggest that the incidence of preoperative hypoproteinemia is higher in patients with rectal cancer. Patients with preoperative hypoproteinemia tend to be older, have a lower body mass index, and a higher proportion of pTNM stage Ⅳ. However, it was not found that preoperative hypoproteinemia is a risk factor for postoperative complications.
ObjectiveTo analyze the association between preoperative staging (AJCC-TNM) and neoadjuvant therapy regimen decision-making and efficacy in patients with rectal cancer in the current version of Database from Colorectal Cancer (DACCA). MethodsThe data analysis for this study selected the DACCA version updated on April 20, 2024. The patient information was collected and categorized into three stages (Ⅱ, Ⅲ, and Ⅳ). The differences in neoadjuvant treatment decision-making and therapeutic effects, including gross changes, imaging changes, and tumor regression grade (TRG), were analyzed. ResultsA total of 3 158 eligible cases were collected in this study, with complete preoperative staging and neoadjuvant therapy decision-making data available for 2 370 (75.0%) patients. There were statistically significant differences in the overall comparison among the patients with rectal cancer in terms of the selection of combined targeted therapy, radiotherapy regimens, and the intensity of neoadjuvant chemotherapy by patients at different preoperative stages (χ²=42.239, P<0.001; χ²=41.615, P<0.001; H=1.161, P=0.004). Specifically, the proportion of patients choosing combined targeted therapy and combined radiotherapy gradually increased as the stage advanced. Among patients at different stages, the proportion of those choosing medium-course chemotherapy was the highest, and the proportion of patients choosing long-course chemotherapy was the highest among those with more advanced stages. Regarding the gross changes, imaging changes, and TRG results after neoadjuvant treatment in the patients at different preoperative stages, there were statistically significant differences in the overall comparison among patients with stage Ⅱ, Ⅲ, and Ⅳ rectal cancer (H=7.860, P=0.020; H=9.845, P=0.007; H=6.680, P=0.035). The proportion of partial response was the highest across all response metrics (macroscopic, radiographic, and TRG) in each stage. Notably, stage II patients demonstrated the highest rate of complete response. For TRG evaluation, grade 2 (TRG2) was the most common outcome across all stages. ConclusionsData analysis from DACCA reveals that patients with advanced stages are more likely to choose chemotherapy combined with targeted therapy or radiotherapy, and had a higher proportion of intermediate range chemotherapy and the intensity of neoadjuvant chemotherapy is stronger. In terms of neoadjuvant treatment effects, the earlier the staging, the better the gross and imaging changes, and the lower the TRG level.
